Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of ($0.29), $0.08 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $212.5 million versus the consensus estimate of $192.9 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi